Marksans Pharma Ltd announces US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that it has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC).

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR DelayedRelease Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals LP.

Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux ane ulcer). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers and is expected to help prevent cancer of the esophagus. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

The product will be manufactured at the Company's formulation manufacturing facility in Goa, India.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 109.95 as compared to the previous close of Rs. 108.95. The total number of shares traded during the day was 254834 in over 2801 trades.

The stock hit an intraday high of Rs. 111.40 and intraday low of 108.70. The net turnover during the day was Rs. 28017209.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 USFDA Approval ANDA EsomeprazoleMagnesium DelayedReleaseCapsules